Kainos Medicine, Inc. (KOSDAQ:284620)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,087.00
-105.00 (-8.81%)
At close: Aug 14, 2025

Kainos Medicine Statistics

Total Valuation

Kainos Medicine has a market cap or net worth of KRW 35.56 billion. The enterprise value is 37.38 billion.

Market Cap 35.56B
Enterprise Value 37.38B

Important Dates

The last earnings date was Friday, November 14, 2025.

Earnings Date Nov 14, 2025
Ex-Dividend Date n/a

Share Statistics

Kainos Medicine has 32.71 million shares outstanding. The number of shares has increased by 8.89% in one year.

Current Share Class 32.71M
Shares Outstanding 32.71M
Shares Change (YoY) +8.89%
Shares Change (QoQ) -8.05%
Owned by Insiders (%) 22.73%
Owned by Institutions (%) n/a
Float 22.95M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 37.87
PB Ratio 4.54
P/TBV Ratio 20.54
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -3.68
EV / Sales 39.81
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -5.85

Financial Position

The company has a current ratio of 3.00, with a Debt / Equity ratio of 0.03.

Current Ratio 3.00
Quick Ratio 2.43
Debt / Equity 0.03
Debt / EBITDA n/a
Debt / FCF -0.04
Interest Coverage -243.10

Financial Efficiency

Return on equity (ROE) is -95.23% and return on invested capital (ROIC) is -50.64%.

Return on Equity (ROE) -95.23%
Return on Assets (ROA) -46.11%
Return on Invested Capital (ROIC) -50.64%
Return on Capital Employed (ROCE) -113.60%
Revenue Per Employee n/a
Profits Per Employee n/a
Employee Count n/a
Asset Turnover 0.08
Inventory Turnover n/a

Taxes

In the past 12 months, Kainos Medicine has paid 1.14 million in taxes.

Income Tax 1.14M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -73.03% in the last 52 weeks. The beta is 1.27, so Kainos Medicine's price volatility has been higher than the market average.

Beta (5Y) 1.27
52-Week Price Change -73.03%
50-Day Moving Average 1,104.96
200-Day Moving Average 1,939.78
Relative Strength Index (RSI) 50.94
Average Volume (20 Days) 481,084

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Kainos Medicine had revenue of KRW 938.87 million and -10.15 billion in losses. Loss per share was -334.62.

Revenue 938.87M
Gross Profit 657.00M
Operating Income -8.94B
Pretax Income -10.15B
Net Income -10.15B
EBITDA -8.19B
EBIT -8.94B
Loss Per Share -334.62
Full Income Statement

Balance Sheet

The company has 4.22 billion in cash and 225.96 million in debt, giving a net cash position of 4.00 billion or 122.15 per share.

Cash & Cash Equivalents 4.22B
Total Debt 225.96M
Net Cash 4.00B
Net Cash Per Share 122.15
Equity (Book Value) 7.83B
Book Value Per Share 69.55
Working Capital 3.76B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -6.38 billion and capital expenditures -5.52 million, giving a free cash flow of -6.39 billion.

Operating Cash Flow -6.38B
Capital Expenditures -5.52M
Free Cash Flow -6.39B
FCF Per Share -195.21
Full Cash Flow Statement

Margins

Gross Margin 69.98%
Operating Margin -952.20%
Pretax Margin -1,080.64%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Kainos Medicine does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -8.89%
Shareholder Yield -8.89%
Earnings Yield -28.54%
FCF Yield -17.96%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on June 24, 2022. It was a reverse split with a ratio of 0.2.

Last Split Date Jun 24, 2022
Split Type Reverse
Split Ratio 0.2

Scores

Kainos Medicine has an Altman Z-Score of -2.79 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -2.79
Piotroski F-Score 2